複雑性尿路感染症に対するホスホマイシンとジベカシンの併用療法の臨床的検討

DOI

書誌事項

タイトル別名
  • CLINICAL INVESTIGATION ON TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS WITH FOSFOMYCIN IN COMBINATION WITH DIBEKACIN

抄録

Fourteen patients were administered fosfomycin in combination with dibekacin to investigate the usefulness of this combined therapy against complicated urinary tract infections. The former was given in a single dose of 2g twice a day by intravenous drip infusion, while the latter a single dose of 50 mg twice a day intramuscularly, both for 5 days. The clinical and bacteriological efficacy, and side effects were then evaluated and the in vitro combined effect of the drugs on 6 strains of clinical isolates was also found by chequer board method.<BR>1. Overall, the combined therapy of fosfomycin and dibekacin was clinically effective in 78.6% of 14 patients with complicated urinary tract infections.<BR>2. Twelve (71%) of the 17 strains of 8 bacterial species were eradicated by the therapy.<BR>3. Combined efficacy by chequer board method was found against Escherichia coli, Pseudomonas aeruginosa, Pseudomonas cepacia, Pseudomonas morganii, Pseudomonas rettgeri and Serratia marcescens.<BR>4. There were no subjective or objective clinical side effects. No appreciable change was seen in the results of clinical and laboratory data on peripheral blood and renal function tests, nor was there any change in the results of hepatic function tests except slight and transient rises in the serum GOT and GPT levels in several cases.<BR>5. From the above-mentioned results, we think that combined therapy with fosfomycin and dibekacin is useful in the treatment of complicated urinary tract infections.

収録刊行物

詳細情報 詳細情報について

  • CRID
    1390282681254965376
  • NII論文ID
    130004193702
  • DOI
    10.11250/chemotherapy1953.30.871
  • ISSN
    18845894
    00093165
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ